News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results